Professor Ernest Choy

2021

• Rehberg, M.et al. 2021. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatology and Therapy 8, pp. 1661-1675. (10.1007/s40744-021-00361-5)
• Quartuccio, L. and Choy, E. H. 2021. Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis. Rheumatology 60(11), pp. 4953-4955., article number: keab425. (10.1093/rheumatology/keab425)
• Fernández-Gutiérrez, F.et al. 2021. Mining primary care electronic health records for automatic disease phenotyping: a transparent machine learning framework. Diagnostics 11(10), article number: 1908. (10.3390/diagnostics11101908)
• Rehberg, M.et al. 2021. Correction to: identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatology and Therapy 8(4), pp. 1921–1922. (10.1007/s40744-021-00389-7)
• D'Amico, F.et al. 2021. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmunity Reviews 20(7), article number: 102849. (10.1016/j.autrev.2021.102849)
• Cooksey, R.et al. 2021. Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK. Rheumatology Advances in Practice 5(2), article number: rkab042. (10.1093/rap/rkab042)
• Takala, R.et al. 2021. Anti-inflammatory and immunoregulatory effects of pinolenic acid in rheumatoid arthritis. Rheumatology (10.1093/rheumatology/keab467)
• Bamias, A.et al. 2021. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open 6(3), article number: 100152. (10.1016/j.esmoop.2021.100152)
• Xu, C.et al. 2021. Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters. Journal of Clinical Pharmacology 61(5), pp. 714-724. (10.1002/jcph.1795)
• Pedley, R.et al. 2021. Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. Rheumatology Advances in Practice 5(2), article number: rkaa063. (10.1093/rap/rkaa063)
• Pope, J. E. and Choy, E. H. 2021. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Seminars in Arthritis and Rheumatism 51(1), pp. 219-229. (10.1016/j.semarthrit.2020.11.005)
• Simon, L. S.et al. 2021. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 51(1), pp. 278-284. (10.1016/j.semarthrit.2020.10.008)
• Choy, E.et al. 2021. Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatology 5(1), article number: 3. (10.1186/s41927-020-00173-0)
• Kostine, M.et al. 2021. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases 80(1), pp. 36-48. (10.1136/annrheumdis-2020-217139)
• Nagy, G.et al. 2021. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 80(1), pp. 31-35. (10.1136/annrheumdis-2020-217344)
• Humby, F.et al. 2021. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397(10271), pp. 305-317. (10.1016/S0140-6736(20)32341-2)

2020

• Pitzalis, C., Choy, E. H. S. and Buch, M. H. 2020. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nature Reviews Rheumatology 16(10), pp. 590-599. (10.1038/s41584-020-0491-4)
• Loriot, Y.et al. 2020. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer 138, pp. 202-211. (10.1016/j.ejca.2020.07.023)
• Leung, M., Choy, E. H. and Lau, C. 2020. Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. Seminars in Arthritis and Rheumatism 50(4), pp. 749-758. (10.1016/j.semarthrit.2020.03.010)
• Ho, K. Y.et al. 2020. Practice advisory on the appropriate use of NSAIDs in primary care. Journal of Pain Research 2020(13), pp. 1925-1939. (10.2147/JPR.S247781)
• Choy, E. H.et al. 2020. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology 16, pp. 335-345. (10.1038/s41584-020-0419-z)
• Thompson, C.et al. 2020. CD28− Cells are increased in early rheumatoid arthritis and are linked with cytomegalovirus status. Frontiers in Medicine 7, article number: 129. (10.3389/fmed.2020.00129)
• Winthrop, K. L.et al. 2020. Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Annals of the Rheumatic Diseases 79, pp. 669-671. (10.1136/annrheumdis-2019-216566)
• Monnet, E.et al. 2020. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Annals of the Rheumatic Diseases 79, pp. 316-323. (10.1136/annrheumdis-2019-216487)
• Pell, B.et al. 2020. Using visual timelines in telephone interviews: Reflections and lessons learned from the STAR Family Study. International Journal of Qualitative Methods 19, pp. 1-11. (10.1177/1609406920913675)

2019

• Lliso-Ribera, G.et al. 2019. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Annals of the Rheumatic Diseases 78(12), pp. 1642-1652. (10.1136/annrheumdis-2019-215751)
• Choy, E. H. and Dures, E. 2019. Fatigue in rheumatoid arthritis. Rheumatology 58(S5), pp. v1-v2. (10.1093/rheumatology/kez314)
• Demmler, J. C.et al. 2019. Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open 9(11), article number: e031365. (10.1136/bmjopen-2019-031365)
• Choy, E. H. 2019. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology 58(S5), pp. v51-v55. (10.1093/rheumatology/kez389)
• Ramjeeawon, A. and Choy, E. 2019. Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing. Clinical Rheumatology 38(11), pp. 3153-3159. (10.1007/s10067-019-04656-5)
• Williams, D.et al. 2019. “Nobody knows, or seems to know how rheumatology and breastfeeding works”: Women's experiences of breastfeeding whilst managing a long-term limiting condition – A qualitative visual methods study. Midwifery 78, pp. 91-96. (10.1016/j.midw.2019.08.002)
• Pickles, T.et al. 2019. Adaptive trial designs in rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology 46(10), pp. 1406-1408., article number: jrheum.181054. (10.3899/jrheum.181054)
• Hewlett, S.et al. 2019. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations. Health Technology Assessment 23(57), pp. 1. (10.3310/hta23570)
• Choy, E. H. 2019. Using biologics safely. Rheumatology 58(9), pp. 1515-1516. (10.1093/rheumatology/kez129)
• Lewis, M. J.et al. 2019. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Reports 28(9), pp. 2455-2470.e5. (10.1016/j.celrep.2019.07.091)
• Mease, P.et al. 2019. Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. European Journal of Rheumatology 6(3), pp. 113-121. (10.5152/eurjrheum.2019.19057)
• Baerwald, C. and Choy, E. 2019. Generalised musculoskeletal problems. Best Practice & Research Clinical Rheumatology 33(3), article number: 101441. (10.1016/j.berh.2019.101441)
• Choy, E.et al. 2019. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and Experimental Rheumatology 37(4), pp. 694-407., article number: CER11619.
• Tarp, S.et al. 2019. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 48(6), pp. 958-966. (10.1016/j.semarthrit.2018.10.002)
• Choy, E. H. 2019. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology 58(6), pp. 953-962., article number: key339. (10.1093/rheumatology/key339)
• Choy, E.et al. 2019. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology 58(6), pp. 1056-1064. (10.1093/rheumatology/key393)
• Humby, F.et al. 2019. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases 78(6), pp. 761-772. (10.1136/annrheumdis-2018-214539)
• Macfarlane, G. J.et al. 2019. AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology 3(1), pp. -., article number: 19. (10.1186/s41927-019-0066-7)
• Isaacs, J. D.et al. 2019. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatology Advances in Practice 3(1), pp. -. (10.1093/rap/rkz010)
• Sternberg, C. N.et al. 2019. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. European Urology (10.1016/j.eururo.2019.03.015)
• Hewlett, S.et al. 2019. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Annals of the Rheumatic Diseases 78(4), pp. 465-472. (10.1136/annrheumdis-2018-214469)
• Jones, S. A.et al. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
• Takeuchi, T.et al. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
• Smolen, J. S.et al. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
• Choy, E.et al. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
• Choy, E.et al. 2019. The need for comparative data in spondyloarthritis. Arthritis Research and Therapy 21(1), article number: 32. (10.1186/s13075-019-1812-3)
• Strand, V.et al. 2019. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research 8(7), pp. 497-510. (10.2217/cer-2018-0141)
• Choy, E.et al. 2019. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open 5(1), article number: e000798. (10.1136/rmdopen-2018-000798)

2018

• Piguet, V. and Choy, E. 2018. Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?. British Journal of Dermatology 179(6), pp. 1233-1234. (10.1111/bjd.16230)
• Thompson, C., Piguet, V. and Choy, E. 2018. The pathogenesis of dermatomyositis. British Journal of Dermatology 179(6), pp. 1256-1262. (10.1111/bjd.15607)
• Cooksey, R.et al. 2018. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Seminars in Arthritis and Rheumatism 48(3), pp. 367-373. (10.1016/j.semarthrit.2018.03.005)
• Jordan, L. A.et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57(11), pp. 2042-2052. (10.1093/rheumatology/key196)
• Macfarlane, G. J.et al. 2018. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology 57(11), pp. 1982-1990., article number: key206. (10.1093/rheumatology/key206)
• Vollenhoven, R.et al. 2018. Evaluation of the short‐, mid‐, and long‐term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis and Rheumatology 71(5), pp. 685-695. (10.1002/art.40780)
• McInnes, I. B.et al. 2018. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research 7(11), pp. 1107-1123. (10.2217/cer-2018-0075)
• Just, S. A.et al. 2018. Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open 4(2), pp. e000799. (10.1136/rmdopen-2018-000799)
• Pamfil, C. and Choy, E. 2018. Functional MRI in rheumatic disease with a focus on fibromyalgia. Clinical and Experimental Rheumatology 36 Sup(5), pp. 82-85., article number: 114.
• Phillips, R.et al. 2018. Identifying the unmet information and support needs of women with autoimmune rheumatic diseases during pregnancy planning, pregnancy and early parenting: mixed-methods study. BMC Rheumatology 2, article number: 21. (10.1186/s41927-018-0029-4)
• Pickles, T.et al. 2018. Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice 2(2), article number: rky045. (10.1093/rap/rky045)
• Dolton, G.et al. 2018. Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells. Frontiers in Immunology 9, article number: 1378. (10.3389/fimmu.2018.01378)
• Phillips, R.et al. 2018. Reaching a consensus on research priorities for supporting women with autoimmune rheumatic diseases during pre-conception, pregnancy and early parenting: A Nominal Group Technique exercise with lay and professional stakeholders. Wellcome Open Research 3, article number: 75. (10.12688/wellcomeopenres.14658.1)
• O'Mahony, A.et al. 2018. Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of Translational Medicine 16, article number: 156. (10.1186/s12967-018-1532-5)
• Nurmohamed, M.et al. 2018. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Safety 41(5), pp. 473-488. (10.1007/s40264-017-0628-9)
• Arnold, L. M.et al. 2018. An evidence-based review of pregabalin for the treatment of fibromyalgia. Current Medical Research and Opinion 34(8), pp. 1397-1409. (10.1080/03007995.2018.1450743)
• Choy, E.et al. 2018. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology 57(3), pp. 499-507. (10.1093/rheumatology/kex443)
• Sarzi-Puttini, P.et al. 2018. Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. Autoimmunity Reviews 17(1), pp. 33-35. (10.1016/j.autrev.2017.11.007)

2017

• Choy, E. H. S. and Calabrese, L. H. 2017. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rhuematology 57(11), pp. 1885-1895. (10.1093/rheumatology/kex391)
• Macfarlane, G. J.et al. 2017. EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases 76(12), pp. -., article number: e54. (10.1136/annrheumdis-2017-211587)
• Choy, E. H. S.et al. 2017. Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study. Arthritis Care & Research 69(10), pp. 1484-1494. (10.1002/acr.23303)
• Cohen, S.et al. 2017. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the Rheumatic Diseases 76(10), pp. 1679-1687. (10.1136/annrheumdis-2016-210459)
• Winthrop, K. L.et al. 2017. The safety and immunogenicity of live Zoster Vaccination in patients with rheumatoid arthritis before starting Tofacitinib: a randomized phase II trial. Arthritis & Rheumatology 69(10), pp. 1969-1977. (10.1002/art.40187)
• Orr, C.et al. 2017. Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology 13(8), pp. 463-475. (10.1038/nrrheum.2017.115)
• Sime, K., Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6(2), pp. 87-101. (10.1080/21623945.2017.1295174)
• Kosek, E.et al. 2017. Lower placebo responses after long-term exposure to fibromyalgia pain. Journal of Pain 18(7), pp. 835-843. (10.1016/j.jpain.2017.02.434)
• Burmester, G. R.et al. 2017. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76, pp. 1078-1085. (10.1136/annrheumdis-2016-210297)
• Fleischmann, R. F.et al. 2017. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatology and Therapy 4(1), pp. 57-69. (10.1007/s40744-017-0060-8)
• Kia, S. and Choy, E. 2017. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines 5(2), article number: 20. (10.3390/biomedicines5020020)
• Choy, E.et al. 2017. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56(5), pp. 689-697. (10.1093/rheumatology/kew271)
• Low, A. S. L.et al. 2017. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76(4), pp. 654-660. (10.1136/annrheumdis-2016-209784)
• Macfarlane, G. J.et al. 2017. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 76(2), pp. 318-328. (10.1136/annrheumdis-2016-209724)

2016

• Leung, A. M. H.et al. 2016. Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. Rhuematology 55(11), pp. 1954-1958. (10.1093/rheumatology/kew279)
• Rawlings, C., Davies, R. and Choy, E. 2016. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 86, pp. 92-99. (10.1016/j.cyto.2016.07.015)
• Owen, E., Choy, E. and Piguet, V. 2016. Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. British Journal of Dermatology 175(4), pp. 665-666. (10.1111/bjd.14917)
• Taylor, A. M.et al. 2016. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain 157(9), pp. 1836-1850. (10.1097/j.pain.0000000000000577)
• Porter, D.et al. 2016. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388(10041), pp. 239-247. (10.1016/S0140-6736(16)00380-9)
• Choy, E. H. 2016. Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia. Pain Management 6(4), pp. 339. (10.2217/pmt-2016-0009)
• Almeida, C.et al. 2016. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews (10.1002/14651858.CD008334.pub2)
• Tarp, S.et al. 2016. Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism 46(6), pp. 699-708. (10.1016/j.semarthrit.2016.09.003)
• Zhou, S.et al. 2016. Defining disease phenotypes in primary care electronic health records by a machine learning approach: A case study in identifying rheumatoid arthritis. PLOS ONE 11(5), pp. e0154515. (10.1371/journal.pone.0154515)
• Davies, R.et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
• Bykerk, V. P.et al. 2016. Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open 2(1), article number: e000225. (10.1136/rmdopen-2015-000225)
• Taylor, A.et al. 2016. Defining chronic pain reply. Journal of Rheumatology 43(4), pp. 826-827. (10.3899/jrheum.151456)
• Marchettini, P.et al. 2016. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain 20(3), pp. 472-482. (10.1002/ejp.763)
• Liu, X.et al. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
• Arnold, L. M., Gebke, K. B. and Choy, E. 2016. Fibromyalgia: management strategies for primary care providers. International Journal of Clinical Practice 70(2), pp. 99-112. (10.1111/ijcp.12757)
• Ravindran, V. and Choy, E. 2016. Modified-release prednisone in rheumatoid arthritis: Rationale for chronotherapy, mechanistic considerations, and clinical implications. Indian Journal of Rheumatology 11(4), pp. 216-221.

2015

• Taylor, A. M.et al. 2015. Is chronic pain a disease in its own right? Discussions from a Pre-OMERACT 2014 Workshop on chronic pain. Journal of Rheumatology 42(10), pp. 1947-1953. (10.3899/jrheum.141328)
• Phillips, K.et al. 2015. Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology 42(10), pp. 1943-1946., article number: 194386. (10.3899/jrheum.141386)
• Choy, E.et al. 2015. Treatment of Rheumatoid Arthritis with an anti-tumour necrosis factor agent or Tocilizumab as first biologic therapy: Action, a global comparative observational study. Rheumatology 55(Supp 1), pp. 101-102. (10.1093/rheumatology/kew144.023)
• Hewlett, S.et al. 2015. Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approaches. BMJ Open 5(8), article number: e009061. (10.1136/bmjopen-2015-009061)
• Giles, J. L.et al. 2015. Response to comment on 'Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis'. Journal of Immunology 195(1), pp. 4-4. (10.4049/jimmunol.1500968)
• Ibrahim, F.et al. 2015. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rhuematology 54(6), pp. 1050-1055. (10.1093/rheumatology/keu442)
• Choy, E. H. S. 2015. The role of sleep in pain and fibromyalgia. Nature Reviews Rheumatology 11(9), pp. 513-520. (10.1038/nrrheum.2015.56)
• Collins, F. L.et al. 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015, pp. -., article number: 901679. (10.1155/2015/901679)
• Giles, J.et al. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194(7), pp. 3029-3034. (10.4049/jimmunol.1402956)

2014

• Lipkovich, I. A.et al. 2014. Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients. BMC Musculoskeletal Disorders 15, article number: 450. (10.1186/1471-2474-15-450)
• Giles, J. L.et al. 2014. Functional analysis of a complement polymorphism (rs17611) associated with Rheumatoid Arthritis. Immunology 143(s2), pp. 181-182. (10.1111/imm.12407)
• Jensen, K. B.et al. 2014. Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia. The Journal of Pain 15(12), pp. 1328-1337. (10.1016/j.jpain.2014.09.011)
• Baron, R.et al. 2014. Improving the primary care physicians' decision making for fibromyalgia in clinical practice: development and validation of the Fibromyalgia Detection (FibroDetect®) screening tool. Health and Quality of Life Outcomes 12, article number: 128. (10.1186/s12955-014-0128-x)
• Lie, E.et al. 2014. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study. Annals of the Rheumatic Diseases 73, pp. 1781. (10.1136/annrheumdis-2013-203496)
• Kirwan, J. R.et al. 2014. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. Journal of Rheumatology 41(5), pp. 994-999. (10.3899/jrheum.131309)
• Tugwell, P.et al. 2014. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. Journal of Rheumatology 41(5), pp. 1000-1004. (10.3899/jrheum.131310)
• Bykerk, V. P.et al. 2014. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. Journal of Rheumatology 41(4), pp. 799-809. (10.3899/jrheum.131252)
• Kirwan, J. R.et al. 2014. Updating the OMERACT filter: implications for patient-reported outcomes. Journal of Rheumatology 41(5), pp. 1011-1015. (10.3899/jrheum.131312)
• Davies, R. and Choy, E. 2014. Clinical experience of IL-6 blockade in rheumatic diseases: implications on IL-6 biology and disease pathogenesis. Seminars in Immunology 26(1), pp. 97-104. (10.1016/j.smim.2013.12.002)
• Rawlings, C. and Choy, E. 2014. The future of biological agents in the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 9(5), pp. 475-486. (10.2217/ijr.14.32)

2013

• Bari, S. F. and Choy, E. H. S. 2013. Outcome measures in rheumatoid arthritis. Indian Journal of Rheumatology 8(SUPPL1), pp. S31-S35. (10.1016/j.injr.2013.11.011)
• van der Maas, A.et al. 2013. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases 72(11), pp. 1800-1805. (10.1136/annrheumdis-2012-202281)
• Gullick, N.et al. 2013. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clinical and Experimental Immunology 174(2), pp. 292-301. (10.1111/cei.12167)
• Ceeraz, S.et al. 2013. Defective CD8+CD28?regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clinical and Experimental Immunology 174(1), pp. 18-26. (10.1111/cei.12161)
• Choy, E. H.et al. 2013. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Research and Therapy 15(5), article number: R132. (10.1186/ar4312)
• Smolen, J.et al. 2013. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases 72(4), pp. 482-492. (10.1136/annrheumdis-2012-202469)
• Petzke, F.et al. 2013. Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia. Scandinavian Journal of Pain 4(2), pp. 65-74. (10.1016/j.sjpain.2012.10.002)
• Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
• Jensen, K. B.et al. 2013. Overlapping structural and functional brain changes in patients with long-term exposure to fibromyalgia pain. Arthritis & Rheumatism 65(12), pp. 3293-3303. (10.1002/art.38170)

2012

• Collins, F.et al. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64(10), pp. S768-S768.
• Spaeth, M.et al. 2012. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: Results of an international phase 3 trial. Annals of the Rheumatic Diseases 71(6), pp. 935-942. (10.1136/annrheumdis-2011-200418)

2011

• Choy, E. H. S.et al. 2011. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism 41(3), pp. 335-345.e6. (10.1016/j.semarthrit.2011.06.003)
• Paringe, V.et al. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
• Smale, S.et al. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.

2010

• Jensen, K. B.et al. 2010. Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. Arthritis & Rheumatism 62(11), pp. 3488-3495. (10.1002/art.27649)

2008

• Choy, E. H. S.et al. 2008. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Care and Research 59(2), pp. 192-199. (10.1002/art.23342)
• Ravindran, V., Scott, D. L. and Choy, E. H. S. 2008. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Annals of the Rheumatic Diseases 67(6), pp. 855-859. (10.1136/ard.2007.072652)
• Choy, E. H. S.et al. 2008. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Annals of the Rheumatic Diseases 67(5), pp. 656-663. (10.1136/ard.2007.076299)